Lindsay A.M. Rein, MD

Dr. Lindsay Rein is an Assistant Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke. She earned her M.D. from the University of North Dakota School of Medicine and Health Sciences and went on to complete both her Internal Medicine residency training as well as her Hematology and Medical Oncology fellowship training at Duke before joining the faculty in 2014.  Dr. Rein is a physician-scientist with a specific interest in the development of novel targeted therapies for patients with myeloid malignancies. 

Her laboratory research focuses on the role of β-arrestins, scaffolding, and signaling proteins involved in adrenergic signaling in myeloproliferative neoplasms. Clinically, Dr. Rein treats patients with myeloproliferative disorders and runs a program of both early and late phase clinical trials for patients with various MPNs including systemic mastocytosis.  She is a panel member for the NCCN guidelines and is also a member of the H Jean Khoury Cure CML Consortium.